Modern biological oncotherapy of solid tumours means targeting various kinase inhibitor pathways either by specific monoclonal antibodies against extracellular receptors or ligands (trastuzumab, cetuximab, panitumumab, bevacizumab) or by small molecular weight oral kinase inhibitors that interfere with intracellular signal transduction (imatinib, sunitinib, lapatinib, erlotinib, gefitinib, sorafenib). Here we review the clinical use of targeted biological agents in breast and colorectal cancer.
|Translated title of the contribution||Molecularly targeted biological therapy in the treatment of solid tumours part one - Breast cancer and colorectal cancer|
|Number of pages||6|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Sep 1 2007|
ASJC Scopus subject areas